Drug Trial Radar · NCT01708629
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
Last checked: Nov 20, 2026Latest source record: Jan 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,881
Actual
Start
Sep 2012
Primary completion
Aug 2014
Study completion Oct 2015
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.
Conditions
- Plaque Psoriasis
Interventions
210 mg brodalumabDrug
210 mg brodalumab administered SC
140 mg brodalumabDrug
140 mg brodalumab administered SC
ustekinumabDrug
45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
placeboDrug
placebo administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12Time frame: 12 weeks
- Percentage of Participants With Static Physician Global Assessment (sPGA) Success Score (Score of 0 or 1) at Week 12 - Comparison to PlaceboTime frame: 12 weeks
Locations
157 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Mobile, Alabama
Research Site
Phoenix, Arizona
Research Site
Beverly Hills, California
Research Site
Burbank, California
Research Site
Encino, California
Research Site
Fremont, California
Research Site
Fullerton, California
Research Site
Irvine, California
Research Site
Los Angeles, California
Research Site
Riverside, California
Research Site
Sacramento, California
Research Site
San Diego, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
Denver, Colorado
Research Site
Farmington, Connecticut
Research Site
Trumbull, Connecticut
Research Site
Boca Raton, Florida
Research Site
Coral Gables, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Tamarac, Florida
Research Site
Alpharetta, Georgia
Research Site
Atlanta, Georgia
Research Site
Macon, Georgia
Research Site
Boise, Idaho
Research Site
Arlington Heights, Illinois
Research Site
Champaign, Illinois
Research Site
Maywood, Illinois
Research Site
Normal, Illinois
Research Site
Wheaton, Illinois
Research Site
Indianapolis, Indiana
Research Site
New Albany, Indiana
Research Site
Overland Park, Kansas
Research Site
Overland Park, Kansas
Research Site
Louisville, Kentucky
Research Site
Owensboro, Kentucky
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.